New insulin rival tested in 550 chinese patients with type 1 diabetes
NCT ID NCT07282054
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tested a new insulin called THDB0206 against a standard insulin (lispro) in 550 Chinese adults with type 1 diabetes. Both groups also used a long-acting insulin (glargine). The main goal was to see how well the new insulin controls blood sugar over 26 weeks. Participants were between 18 and 75 years old and had diabetes for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower hospital
Nanjing, China
Conditions
Explore the condition pages connected to this study.